ocal HDR brachytherapy in case of localized prostate cancer - ProFocA

niversitätsklinik für Radiologie und Nuklearmedizin0 个研究点目标入组 37 人开始时间: 2016年8月29日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patients between 18 and 80 years, with a localized tumor of the prostate under low-risk or intermediate risk early to D'Amico, the standard procedures, such as percutaneous radiotherapy, radical prostatectomy or active surveillance refuse.
•In preoperatively performed multiparametric MRI (mpMRT) at least one suspicious lesion with a PI-RADS score must be described by 4/5.
•Age 18 aged 80 or a life expectancy of at least 10 years
•MR biopsy or prostate fusionsbioptisch secured
•In accordance distinctly visible index lesions with PI-RADS score 4/5
•consent of focal treatment by using brachytherapy
•refusal of also introduced standard treatments

•several suspect lesion in mpMRT with a PI-RADS score of 4/5. Furthermore, symptoms that preoperatively additional treatments of the prostate makes necessary (z. B. TURP) equipment and other obstacles which do not allow to carry out the therapy.
•Missing capacity to consent
•evidence of lymph node or metastasis in the CT or MRI
•no suspect MR lesion (PIRADS 4/5)
•several suspect MR lesions (PIRADS 4/5)
•ongoing antihormonal therapy

发起方

niversitätsklinik für Radiologie und Nuklearmedizin